Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 for Platelet Engraftment After Haplo-HSCT
NCT07321626Phase 1Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jun 2025
- Primary completion
- Dec 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of romiplostim in Delayed platelet engraftment (DPE) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Cumulative Platelet Engraftment Rate by Day +21 at 21 days. Started Jun 2025; status: recruiting.
02
Drugs
romiplostim
03
Conditions
Delayed platelet engraftment (DPE)
Beyond the preview
Go deeper on NCT07321626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07321626.